or Try an Advanced Search...

    Technical Analysis for ATHA - Athira Pharma, Inc.

    Grade Last Price % Change Price Change
    F 2.14 -1.83% -0.04
    ATHA closed down 1.83 percent on Wednesday, May 8, 2024, on 23 percent of normal volume.
    Earnings due: May 9
    *** please verify all earnings dates ***
    0 Watchers
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Up
    Historical ATHA trend table...
    Date Alert Name Type % Chg
    Inside Day Range Contraction 0.00%
    Wide Bands Range Expansion 0.00%
    Crossed Above 20 DMA Bullish -1.83%
    Wide Bands Range Expansion -1.83%
    Doji - Bullish? Reversal 8.63%
    Wide Bands Range Expansion 8.63%
    Oversold Stochastic Weakness 8.63%
    Wide Bands Range Expansion 9.18%
    Gapped Up Strength 9.18%
    Oversold Stochastic Weakness 9.18%
    Older End-of-Day Signals for ATHA ...

       Recent Intraday Alerts

    Alert Time
    Possible Inside Day about 16 hours ago
    Down 3% about 20 hours ago
    Down 2 % about 20 hours ago
    Down 1% about 20 hours ago
    Up 1% about 20 hours ago
    View Earlier Intraday Alerts

    Get a Trading Sidekick!

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Read My Charts!
    Configure default chart indicators
    ATHA Chart by TradingView
    Basic chart:

    Profile

    Athira, headquartered in Seattle, is a drug development company striving to improve human health by advancing bold and innovative therapies with the potential to restore the lives of people impacted by brain disorders. Athira is currently advancing its lead therapeutic candidate, NDX-1017, a novel small molecule therapeutic, in later-stage clinical trials for Alzheimer’s.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Drug Development Nasdaq 100 Index Innovative Therapies Brain Disorders

    Is ATHA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    May 2 Athira Pharma to Participate in Upcoming May Conferences
    Apr 23 One Athira Pharma Insider Raised Their Stake In The Previous Year
    Apr 11 Athira Pharma Announces Publication of Preclinical Data Highlighting Fosgonimeton Treatment in Models of Alzheimer’s Disease
    Apr 3 Athira Pharma Announces Upcoming Poster Presentation at American Academy of Neurology (AAN) 2024 Annual Meeting
    Mar 29 Is Stryker (SYK) Stock Outpacing Its Medical Peers This Year?
    Mar 8 Athira Pharma Presents Clinical and Preclinical Data Supporting Therapeutic Potential of Fosgonimeton in Alzheimer’s and Parkinson’s Diseases at AD/PD™ 2024 International Conference
    Mar 1 Is Arcutis Biotherapeutics (ARQT) Outperforming Other Medical Stocks This Year?
    Feb 28 Athira Pharma, Inc. (ATHA) is a Great Momentum Stock: Should You Buy?
    Feb 22 Athira Pharma GAAP EPS of -$3.09 beats by $0.25
    Feb 22 Athira Pharma Reports Full Year 2023 Financial Results and Pipeline and Business Updates
    See more ATHA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 4.2984
    52 Week Low 1.33
    Average Volume 345,519
    200-Day Moving Average 2.42
    50-Day Moving Average 2.58
    20-Day Moving Average 2.09
    10-Day Moving Average 2.00
    Average True Range 0.15
    RSI (14) 46.52
    ADX 23.57
    +DI 19.88
    -DI 21.33
    Chandelier Exit (Long, 3 ATRs) 2.26
    Chandelier Exit (Short, 3 ATRs) 2.36
    Upper Bollinger Bands 2.43
    Lower Bollinger Band 1.74
    Percent B (%b) 0.58
    BandWidth 33.12
    MACD Line -0.14
    MACD Signal Line -0.18
    MACD Histogram 0.0447
    Fundamentals Value
    Market Cap 81.44 Million
    Num Shares 38.1 Million
    EPS -3.17
    Price-to-Earnings (P/E) Ratio -0.68
    Price-to-Sales 0.00
    Price-to-Book 0.82
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 2.31
    Resistance 3 (R3) 2.31 2.27 2.28
    Resistance 2 (R2) 2.27 2.22 2.26 2.27
    Resistance 1 (R1) 2.20 2.20 2.18 2.20 2.26
    Pivot Point 2.16 2.16 2.15 2.15 2.16
    Support 1 (S1) 2.09 2.11 2.07 2.09 2.02
    Support 2 (S2) 2.05 2.09 2.04 2.01
    Support 3 (S3) 1.98 2.05 2.00
    Support 4 (S4) 1.98